In conclusion, plasma YKL-40 and IL-6 alone are not useful as new diagnostic biomarkers to identify patients with PC at an early stage or to discriminate between patients with PC and chronic pancreatitis. This evidence concerns the gene IL6 and chronic pancreatitis.